Advaxis, Inc. Lead Drug ADXS11-001 Well-Tolerated in 72 Patients, to Date

Published: Apr 19, 2011

PRINCETON, N.J.--(BUSINESS WIRE)--Dr. John Rothman, EVP of Science and Operations at Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, gave the lead presentation entitled, “The Use of Live Attenuated Listeria that Express LLO-Antigen Fusion Proteins for the Treatment of Cancer” in a Target Meeting webinar held April 16, 2011 entitled “Immunotherapy: a promising way for cancer treatment.”

Back to news